Systemic administration of proteasome inhibitor protects against MPTP neurotoxicity in mice

Cellular and Molecular Neurobiology

Volumn 29, Issue 5, 2009, Pages 769-777

  Oshikawa, Takuya ^a   Kuroiwa, Hayato ^a   Yano, Ryohei ^a   Yokoyama, Hironori ^a   Kadoguchi, Naoto ^a   Kato, Hiroyuki ^b   Araki, Tsutomu ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

Dopamine system; Mice; Parkinson's disease; Proteasome; Western blot analysis

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; CARBOBENZOXY LEVO GAMMA BUTYL LEVO GLUTAMYL LEVO ALANYL LEVO LEUCINAL; DOPAMINE; GLIAL FIBRILLARY ACIDIC PROTEIN; HOMOVANILLIC ACID; PROTEASOME INHIBITOR; TYROSINE 3 MONOOXYGENASE; UBIQUITIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DAMAGE; CONTROLLED STUDY; CORPUS STRIATUM; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NERVE CELL; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; SUBSTANTIA NIGRA; UBIQUITINATION; WESTERN BLOTTING;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BLOTTING, WESTERN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; ENZYME INHIBITORS; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; NEOSTRIATUM; NEURONS; PROTEASOME ENDOPEPTIDASE COMPLEX; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE; UBIQUITIN;

MUS;

EID: 67650792957     PISSN: 02724340     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10571-009-9402-6     Document Type: Article

References (48)

1. T Araki T Kumagai K Tanaka M Matsubara H Kato Y Itoyama 2001 Neuroprotective effect of riluzole in MPTP-treated mice Brain Res 918 176 181 10.1016/S0006-8993(01)02944-4
2. A Bobba N Canu A Atlante V Petragallo P Calissano 2002 Proteasome inhibitors prevent cytochrome c release during apoptosis but not in excitotoxic death of cerebellar granule neurons FEBS Lett 515 8 12 10.1016/S0014-5793(02) 02231-7
3. J Bove C Zhou V Jackson-Lewis J Taylor Y Chu HJ Rideout 2006 Proteasome inhibition and Parkinson's disease modeling Ann Neurol 60 260 264 10.1002/ana.20937
4. H Braak K Del Tredici U Rub RA de Vos EN Jansen Steur E Braak 2003 Staging of brain pathology related to sporadic Parkinson's disease Neurobiol Aging 24 197 211 10.1016/S0197-4580(02)00065-9
5. RS Burns CC Chiueh SP Markey MH Ebert DM Jacobowitz IJ Kopin 1983 A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine Proc Natl Acad Sci USA 80 4546 4550 10.1073/pnas.80.14.4546
6. N Canu C Barbato MT Ciotti A Serafino L Dus P Calissano 2000 Proteasome involvement and accumulation of ubiquitinated proteins in cerebellar granule neurons undergoing apoptosis J Neurosci 20 589 599 (Pubitemid 30225561)
7. T Cross 1981 Aquatic actinomycetes: a critical survey of the occurrence, growth and role of actinomycetes in aquatic habitats J Appl Bacteriol 50 397 423 (Pubitemid 11038745)
8. W Dauer S Przedborski 2003 Parkinson's disease: mechanisms and models Neuron 39 889 909 10.1016/S0896-6273(03)00568-3
9. JC Ensign P Normand JP Burden CA Yallop 1993 Physiology of some actinomycete genera Res Microbiol 144 657 660 10.1016/0923-2508(93)90070-I
10. G Fenteany SL Schreiber 1998 Latacystin, proteasome function, and cell fate J Biol Chem 273 8545 8548 10.1074/jbc.273.15.8545
11. F Fornai P Lenzi M Gesi M Ferrucci G Lazzeri CL Busceti 2003 Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition J Neurosci 23 8955 8966 (Pubitemid 37210909)
12. RE Heikkila A Hess RC Duvoisin 1984 Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyidine in mice Science 224 1451 1453 10.1126/science.6610213 (Pubitemid 14123348)
13. SJ Hirst B Ferger 2008 Systemic proteasomal inhibitor exposure enhances dopamine turnover and decreases dopamine levels but does not affect MPTP-induced striatal dopamine depletion in mice Synapse 62 85 90 10.1002/syn.20457
14. M Inoue H Zhai H Sahazaki H Furuyama M Hirima 2004 TMC-95A, a reversible proteasome inhibitor, induces neurite outgrowth in PC12 cells Bioorg Med Chem Lett 14 663 665 10.1016/j.bmcl.2003.11.043
15. NR Jana P Dikshit A Goswami N Nukina 2004 Inhibition of poteasomal function by curcumin induces apoptosis through mitochondrial pathway J Biol Chem 279 11680 11685 10.1074/jbc.M310369200
16. N Kadoguchi H Kimoto R Yano H Kato T Araki 2008 Failure of acute administration with proteasome inhibitor to provide a model of Parkinson's disease in mice Metab Brain Dis 23 147 154 10.1007/s11011-008-9082-9
17. A Kazi DA Urbizu DJ Kuhn AL Acebo ER Jackson GP Greenfelder 2003 A natural musaceas plant extract inhibits proteasome activity and induces apotosis selectively in human tumor and transformed, but not normal and non-transformed, cells Int J Mol Med 12 879 887
18. AF Kisselev AL Goldberg 2001 Proteasome inhibitiors: from research tools to drug candidates Chem Biol 8 739 758 10.1016/S1074-5521(01)00056-4
19. T Kitada S Asakawa N Hattori H Matsumine Y Yamamura S Minoshima 1998 Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism Nature 392 605 608 10.1038/33416
20. Y Koguchi J Kohno M Nishio K Takahashi T Okuda T Ohnuki 2000 TMC-95A, B, C, and D, novel proteasome inhibitors produced by Apiospora montagnei Sacc. Taxonomy, production, isolation, and biological activities J Antibiot 53 105 109 (Pubitemid 30135865)
21. JH Kordower NM Kanaan Y Chu RS Babu J Stansell BT Terpstra 2006 Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys Ann Neurol 60 264 268 10.1002/ana.20935
22. R Kurosaki Y Muramatsu H Kato T Araki 2004 Biochemical, behavioral and immunohistochemical alterations in MPTP-treated mouse model of Parkinson's disease Pharmacol Biochem Behav 78 143 153 10.1016/j.pbb.2004.03.006
23. R Kurosaki Y Muramatsu H Kato Y Watanabe Y Imai Y Itoyama 2005 Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice Eur Neuropsychopharmacol 15 57 67 10.1016/j.euroneuro.2004.05. 007
24. JW Langston P Ballard JW Terud I Irwin 1983 Chronic parkinsonism in humans due to a product of meperidine-analog synthesis Science 219 979 980 10.1126/science.6823561 (Pubitemid 13189531)
25. BN Mathur MD Neely M Dyllick-Brenzinger A Tandon AY Deutch 2007 Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopaminergic degeneration Brain Res 1168 83 89 10.1016/j.brainres.2007.06.076
26. KS McNaught R Belizaire O Isacson P Jenner CW Olanow 2003 Altered proteasomal function in sporadic Parkinson's disease Exp Neurol 179 38 46 10.1006/exnr.2002.8050
27. KS McNaught DP Perl AL Brownell CW Olanow 2004 Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease Ann Neurol 56 149 162 10.1002/ana.20186
28. H Miwa T Kubo A Suzuki K Nishi T Kondo 2005 Retrograde dopaminergic neuron degeneration following intrastriatal proteasome inhibition Neurosci Lett 380 93 98 10.1016/j.neulet.2005.01.024
29. I Momose R Sekizawa H Iinuma T Takeuchi 2002 Inhibition of proteasome activity by tyropeptin A in PC12 cells Biosci Biotechnol Biochem 66 2256 2258 10.1271/bbb.66.2256 (Pubitemid 39251236)
30. S Nam DM Smith QP Dou 2001 Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo J Biol Chem 276 13322 13330 10.1074/jbc.M004209200
31. M Obin E Mesco X Gong AL Haas J Joseph A Taylor 1999 Neurite outgrowth in PC12 cells J Biol Chem 274 11789 11795 10.1074/jbc.274.17.11789
32. LA Pasquini PM Paez MAN Besio Moreno JM Pasquini EF Soto 2003 Inhibition of the protein by lactacystin enhances oligodendroglial cell differentiation J Neurosci 23 4635 4644 (Pubitemid 36712190)
33. L Petrucelli TM Dawson 2004 Mechanism of neurodegenerative disease: role of the ubiquitin proteasome system Ann Med 36 315 320 10.1080/07853890410031948
34. JB Phillips AJ Williams J Adams PJ Elliott FC Tortella 2000 Proteasome inhibitor PS519 reduces infarction and attenuates leukocyte infiltration in rat model of focal cerebral ischemia Stroke 31 1686 1693 (Pubitemid 30437524)
35. A Priyadarshi SA Khuder EA Schaub SS Priyadarshi 2001 Environmental risk factors and Parkinson's disease: a metaanalysis Environ Res 86 122 127 10.1006/enrs.2001.4264
36. R Sadoul PA Fernandez AL Quiquerez I Martinou M Maki M Schroter 1996 Involvement of the proteasome in the programmed cell death of NGF-deprived sympathetic neurons EMBO J 15 3845 3852 (Pubitemid 26289794)
37. H Sawada R Kohno T Kihara Y Izumi N Sakka M Ibi 2004 Proteasome mediates dopaminergic neuronal degeneration, and its inhibition causes alpha-synuclein inclusions J Biol Chem 279 10710 10719 10.1074/jbc.M308434200
38. AH Schapira MW Cletter JR Muddle JM Workman JM Cooper RH King 2006 Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons Ann Neurol 60 253 255 10.1002/ana.20934
39. NY Sherman AL Goldberg 2001 Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases Neuron 29 15 32 10.1016/S0896-6273(01)00177-5
40. N Sin KB Kim M Elofsson L Meng H Auth BH Kwok 1999 Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology Bioorg Med Chem Lett 9 2283 2288 10.1016/S0960-894X(99)00376- 5
41. EJ Song HM Hong YS Yoo 2009 Proteasome inhibition induces neurite outgrowth trough posttranslational modification of TrkA receptor Int J Biochem Cell Biol 41 539 545 10.1016/j.biocel.2008.04.022
42. S Takagi N Hayakawa H Kimoto H Kato T Araki 2007 Damage to oligodendrocytes in the striatum after MPTP neurotoxicity in mice J Neural Transm 114 1553 1557 10.1007/s00702-007-0790-9
43. A Tanaka Y Watanabe H Kato T Araki 2007 Immunohistochemical changes related to ageing in the mouse hippocampus and subventricular zone Mech Ageing Dev 128 303 310 10.1016/j.mad.2007.01.002
44. K van Leyen A Siddiq RR Ratan EH Lo 2005 Proteasome inhibition protects HT22 neuronal cells from oxidative glutamate toxicity J Neurochem 92 824 830 10.1111/j.1471-4159.2004.02915.x
45. Y Watanabe H Kato T Araki 2008 Protective action of neuronal nitric oxide synthase inhibitor in the MPTP mouse model of Parkinson's disease Metab Brain Dis 23 51 69 10.1007/s11011-007-9080-3
46. N Yamamoto H Sawada Y Izumi T Kume H Katsuki S Shimohama 2007 Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress J Biol Chem 282 4364 4372 10.1074/jbc.M603712200
47. H Yokoyama S Takagi Y Watanabe H Kato T Araki 2008 Role of reactive nitrogen and reactive oxygen species against MPTP neurotoxicity in mice J Neural Transm 115 831 842 10.1007/s00702-008-0019-6
48. Y Zhang J Gao KK Chung H Huang VL Dawson TM Dawson 2000 Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1 Proc Natl Acad Sci USA 97 13354 13359 10.1073/pnas.240347797